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Current status and future directions
Mark H. Meissner, MD,a Bo Eklof, MD, PhD,b Joann M. Lohr, MD,c Fedor Lurie, MD, PhD,b,d
Robert Kistner, MD,b,d and Thomas W. Wakefield, MD,e Seattle, Wash; Helsingborg, Sweden; Cincinnati, Ohio;
Honolulu, Hawaii; and Ann Arbor, MichAcute and chronic venous disorders are being increas-
ingly recognized as a healthcare priority in the Western
world. The age- and sex-adjusted incidence of venous
thromboembolism in the United States has been estimated
to be 77.6 per 100,000, corresponding to over 275,000
new cases per year.1 Varicose veins are the most common
clinical manifestation of chronic venous disease, occurring
in one-quarter to one-third of Western adult popula-
tions,2,3 and severe chronic venous insufficiency, with skin
changes and ulceration, may be present in 2% to 5% of
Western populations.4
There has been a corresponding increase in awareness
and interest in venous disease that crosses the boundaries of
many medical specialties. This has been associated with
increasingly sophisticated inquiry into the epidemiology
and pathophysiology of venous disease and the develop-
ment of new pharmaceutical agents, devices, and proce-
dures to treat venous disease. Significant progress has been
made in some areas, such as the development of evidence-
based consensus guidelines for the prophylaxis5 and treat-
ment6 of acute deep venous thrombosis. However, to a
large extent, the investigation, treatment and reporting of
venous disease remains fragmented among a number of
medical specialties, often narrowly focused on specific as-
pects of venous disease. As a result, the quality and content
of the medical literature may differ between specialties,
many clinical practices lack rigorous evidence to support
them, research initiatives are frequently poorly coordi-
nated, and there is a general lack of dialogue between
clinicians, investigators, epidemiologists, and methodolo-
gists both within and between medical specialties.
In an effort to rectify these deficiencies and provide
direction for the future, the 5th Pacific Vascular Sympo-
sium, under the auspices of the American Venous Forum,
was charged with reviewing the current state of knowledge
with respect to acute and chronic venous disease and devel-
oping a roadmap for advancing the field over the next
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doi:10.1016/j.jvs.2007.08.036decade. Accordingly, an international group of recognized
experts (Appendix I) in venous disease from the fields of
dermatology, epidemiology and clinical trials, interven-
tional radiology, hematology, phlebology, and vascular
medicine and surgery, as well as representatives from indus-
try and the National Institutes of Health, was convened for
a 5-day summit from January 20 to 24, 2006. A mission
statement, “To promote venous health through innovative
research, education, and technology” was adopted as a guide
to subsequent discussions.
The process of establishing the current state of knowl-
edge, identifying priorities, and developing a practical,
working plan for the future was accomplished with the
assistance of professional facilitators using a process of
appreciative inquiry.7 The fundamentals of this approach
are designing a plan for the future from a collaborative,
strength-based perspective based on a shared vision of that
future. Recognized experts first established the current
state of knowledge through a 1-day series of intensive
didactic lectures. The remainder of the meeting was de-
voted to the process of identifying areas of deficient knowl-
edge and establishing priorities with respect to necessary
research, improved collaboration between clinicians and
investigators from different medical specialties, and in-
creased professional and patient awareness of venous dis-
ease. This process was accomplished through the interac-
tion of four groups focusing on acute venous disease, the
hemodynamic and diagnostic evaluation of venous disease,
primary chronic venous disease, and secondary chronic
venous disease.
The template followed by each group was similar – first
identifying deficiencies and defining what would constitute
ideal progress 10 years from now, then broadly defining the
priorities for advancing the field of venous disease; narrow-
ing these priorities into goals that could be achieved within
the next 10 years; and developing specific plans for initiat-
ing these projects. At each stage of the process, the prelim-
inary deliberations of the groups were discussed in larger
plenary sessions with input from all participants prior to
proceeding to the next phase.
The didactic proceedings of the symposium, establish-
ing the state of current knowledge, are reviewed in the
following manuscripts addressing acute venous disease, the
hemodynamics and diagnosis of chronic venous disease, pri-
mary chronic venous insufficiency, and secondary chronic
venous insufficiency. The proceedings of a break-out group,
the International Compression Club, addressing the role of
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December Supplement 20072S Meissner et alcompression in venous disorders (Appendix II) is included
in the primary venous disease section. The last manuscript
of this supplement, “The Future of Venous Disease,” rep-
resents the final work product of the symposium and in-
cludes both overall priorities and specific initiatives for
advancing the field of venous disease.
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Appendix I. 5th Pacific Vascular Symposium Participants
Participant Specialty Country
Enrico Ascher Vascular Surgery USA
Dean Bender Industrial Representative
(BSN Jobst)
USA
John J. Bergan Vascular Surgery USA
Charles Biggerstaff Industrial Representative
(W.L. Gore)
USA
Haraldur Bjarnason Interventional Radiology USA
Kevin G. Burnand Vascular Surgery UK
Patrick H. Carpentier Angiology/Vascular
Medicine
France
Robert Carr Industrial Representative
(CR Bard Vascular)
USA
Joseph A. Caprini General Surgery USA
Brian Chase Industrial Representative
(Cook, Inc)
USA
Peter Chelune Industrial Representative
(AstraZeneca)
USA
Sue Chong Industrial Representative
(Sanofi Aventis)
USA
Philip D. Coleridge
Smith
Vascular Surgery UKAppendix I. Continued
Participant Specialty Country
Anthony J. Comerota Vascular Surgery USA
Mark Crowther Hematology Canada
Lian Cunningham Industrial Representative
(VNUS Medical
Technologies)
USA
Michael C. Dalsing Vascular Surgery USA
Konstantinos Delis Vasuclar Surgery Greece
Ralph G. DePalma Vascular Surgery USA
Will Drasler Industrial Representative
(Boston Scientific)
USA
David Doster Industrial Representative
(AngioDynamics)
USA
Steven Elias Vascular Surgery
(Diomed)
USA
Bo G. Eklof Vascular Surgery Sweden
Ermenegildo A. Enrici Vascular Surgery Argentina
Brian Farley Industrial Representative
(VNUS Medical
Technologies)
USA
Thomas Fogarty Vascular Surgeon USA
James Froehlich Vascular Medicine USA
David L. Gillespie Vascular Surgery USA
Peter Gloviczki Vascular Surgery USA
Lazar J. Greenfield Vascular Surgery USA
Jean-Jerome Guex Angiology France
Ahmed Hassan NHLBI USA
Peter K. Henke Vascular Surgery USA
Henry Holzapfel Industrial Representative
(ConvaTec BMS
Medical)
USA
Shunichi Hoshino Cardiovascular Surgery Japan
Jerry Hutchinson Industrial Representative
(BMS Medical)
UK
Russell D. Hull Epidemiology/Internal
Medicine
Canada
Lowell Kabnick Vascular Surgery
(Angiodynamics)
USA
Curtis Kamida Interventional Radiology USA
Brian Katona Industrial Representative
(AstraZeneca)
USA
Robert L. Kistner Vascular Surgery USA
Nicos Labropoulos Vascular Ultrasound USA
Joann M. Lohr Vascular Surgery USA
Christopher Longo Vascular Surgery USA
Fedor Lurie Vascular Surgery USA
Mark A. Mattos Vascular Surgery USA
Robert D. McBane Vascular Medicine USA
Robert B. McLafferty Vascular Surgery USA
Mark H. Meissner Vascular Surgery USA
Greg Moneta Vascular Surgery USA
Nick Morrison General Surgery USA
Peter N. Neglen Vascular Surgery USA
Thomas F. O’Donnell Vascular Surgery USA
Frank T. Padberg Vascular Surgery USA
Peter J. Pappas Vascular Surgery USA
Felicitas Pannier-Fischer Dermatology Germany
Hugo Partsch Dermatology Austria
Dusan Pavcnik Interventional Radiology
(Cook, Inc)
USA
Michel Perrin Vascular Surgery France
David Williams Interventional Radiology USA
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Participants
Joseph A. Caprini
Philip D. Coleridge Smith
Anthony J. Comerota
Konstantinos Delis
Ralph G. DePalma
Jean-Jerome Guex
Fedor Lurie
Gregory Moneta
Felicitas Pannier-Fischer
Hugo Partsch
Eberhard Rabe
C. Vaughn Ruckley
Bauerfeind USA*
BSN-Jobst*
CircAid*
ConvaTec BMS*
Innothera*
Juzo*
Lohmann & Rauscher*
Varitex*
*ICC Industrial SponsorsAppendix I. Continued
Participant Specialty Country
Francoise Pitsch Industrial Representative
(Les Laboratories
Servier)
France
Allesandra Puggioni Vascular Surgery USA
Eberhard Rabe Dermatology Germany
Scott Rader Industrial Representative
(Bacchus Vascular Inc)
USA
Joseph D. Raffetto Vascular Surgery USA
Seshadri Raju Vascular Surgery USA
Graeme Richardson Vascular Surgery Australia
Carl Rickenbaugh Industrial Representative
(CR Bard Vascular)
USA
C. Vaughn Ruckley Vascular Surgery UK
Robert B. Rutherford Vascular Surgery USA
Jocelyn Segal Vascular Surgery USA
Virgillo Vinas Industrial Representative
(BSN Jobst)
USA
J. Leonel Villavicencio Vascular Surgery USA
Thomas W. Wakefield Vascular Surgery USA
Jeff Weitz Hematology Canada
